BridgeBio Pharma, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for BBIO, updated each market day.
BBIO AI Sentiment
AI sees no strong directional signal for BridgeBio Pharma, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Sector
Exchange
Market Cap
$14,640,524,017
Cap Tier
Employees
839
Headquarters
PALO ALTO, CA
Listed Since
June 27, 2019
Website
BBIO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
BBIO Volatility
BridgeBio Pharma, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
